Michael E G Boursnell

Title: Michael E G Boursnell: Innovator in Gene Therapy

Introduction

Michael E G Boursnell is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of gene therapy, particularly through his innovative approaches using herpes viral vectors. His work has the potential to impact therapeutic strategies for various diseases.

Latest Patents

Boursnell holds a patent titled "Methods of gene therapy using herpes viral vectors expressing GM-CSF." This patent describes a genetically disabled mutant virus that has a genome defective in a selected gene essential for producing infectious new virus particles. The virus carries heterologous genetic material encoding an immunomodulatory protein, such as GM-CSF or IL-2. This allows the mutant virus to infect normal host cells and express the immunomodulatory protein, while preventing the production of infectious new virus particles unless it infects recombinant complementing host cells. The applications of this technology include prophylactic and therapeutic uses in generating immune responses, preparing immunogens for tumor therapy, and corrective gene therapy.

Career Highlights

Boursnell is associated with Cantab Pharmaceuticals Research Limited, where he continues to advance his research in gene therapy. His work is characterized by a commitment to developing innovative solutions that harness the power of viral vectors for therapeutic purposes.

Collaborations

Boursnell collaborates with Stephen Charles Inglis, contributing to the advancement of their shared research interests in gene therapy and immunology.

Conclusion

Michael E G Boursnell's contributions to gene therapy through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to lead to significant breakthroughs in therapeutic applications.